BPC-157

BPC-157 was first described in the 1990s by Croatian researchers in the context of gastric mucosal protection. The marketing in the U.S. wellness market focuses on tendon, ligament, and gut healing, with extrapolation from preclinical animal studies.

Preclinical (animal model) studies have reported tendon-to-bone healing acceleration in rats, gastric ulcer protection, modulation of dopaminergic and serotonergic systems in rodent neurological models, and effects on nitric oxide pathways. The body of preclinical research is real and represents the basis for human-use claims.

The critical caveat: there are no large-scale, peer-reviewed, randomized controlled trials of BPC-157 in humans for any of the marketed indications. Long-term human safety, optimal human dosing, and clinical equivalence to standard-of-care interventions are not established.

The FDA placed BPC-157 on the 503A bulks list "Category 2" following review by the FDA Pharmacy Compounding Advisory Committee in 2023. This means licensed pharmacies cannot legally compound BPC-157 for human use under current FDA guidance — it does not have the same regulatory status as compounded GLP-1 prescriptions filled by licensed pharmacies for individual patients.

The "research peptide" supply that dominates online marketing is sold "for research use only / not for human consumption," language that allows the seller to operate outside the regulated drug supply chain. Quality varies dramatically; reports of contaminated, mislabeled, or inactive products are common in this space.